

Eritrea

Tuberculosis profile

Population 2016

5 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.64 (0.29–1.1)	13 (5.9–23)
Mortality (HIV+TB only)	0.075 (0.036–0.13)	1.5 (0.72–2.6)
Incidence (includes HIV+TB)	3.7 (1.7–6.4)	74 (34–129)
Incidence (HIV+TB only)	0.22 (0.14–0.31)	4.4 (2.9–6.3)
Incidence (MDR/RR-TB)**	0.14 (0.028–0.26)	2.9 (0.57–5.2)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.23 (0.081–0.38)	1.2 (0.4–1.9)	1.4 (0.49–2.3)
Males	0.26 (0.092–0.43)	2 (0.7–3.3)	2.3 (0.79–3.7)
Total	0.49 (0.17–0.82)	3.2 (1.1–5.2)	3.7 (1.7–6.4)

TB case notifications, 2016

Total cases notified	2 246
Total new and relapse	2 215
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	65%
- % bacteriologically confirmed among pulmonary	57%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	61% (35–130)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.22 (0.07–0.41)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	132	6%
- on antiretroviral therapy	128	97%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			63 (19–110)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	18% (0.1–36)	
% notified tested for rifampicin resistance	5%	18%	144
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 24, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 24, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	90%	2 061
Previously treated cases, excluding relapse, registered in 2015	85%	34
HIV-positive TB cases registered in 2015	86%	122
MDR/RR-TB cases started on second-line treatment in 2014	67%	24
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	27% (24–29)

TB financing, 2017

National TB budget (US\$ millions)	4.3
Funding source: <1% domestic, 55% international, 45% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically